Floatz logo

CIS-DIAMMINEDICHLOROPLATINUM II

Neoplasms, Nerve Tissue

Hoffmann-La RocheSmall moleculePhase 3Dormant
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
89/ 100

Competitive context

7 Active assets in the Neoplasms, Nerve Tissue cohort.

Asset / SponsorPhaseRating
Carboplatin
Blueprint Medicines Corporation
Phase 3BB
Pembrolizumab
Hoffmann-La Roche
Phase 3BB
Pralsetinib, trans-
Hoffmann-La Roche
Phase 3BB
Microbubble
NaviFUS Corporation
Phase 3B
TASADENOTUREV
DNAtrix, Inc.
Phase 2B

View all 13 →

Same molecule, other indications

CIS-DIAMMINEDICHLOROPLATINUM II is also rated in:

squamous cell lung carcinomaDormant
BBB
Indicative ·
78 / 100
View asset →
primary peritoneal carcinomaDormant
BBB
Indicative ·
77 / 100
View asset →
adenocarcinomaDormant
BBB
Indicative ·
76 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →